District Court Decision Affirmed in U.S. Lovenox(R) (enoxaparin sodium) Patent Infring...( PARIS May 15 /- Sanofi-aventis an...),Health

PARIS, May 15 /PRNewswire-FirstCall/ -- Sanofi-aventis announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the February 8, 2007 decision by the U.S. District Court for the Central District of California in the sanofi-aventis Lovenox(R) patent infringement suit against Amphastar and Teva.

As a result of the Court of Appeals' ruling, the U.S. Lovenox(R) patent is deemed to be unenforceable.

Sanofi-aventis is considering all its legal options.

While several generic manufacturers have requested marketing approval from the FDA for their products alleged to be generic versions of Lovenox(R), sanofi-aventis has not learned of any FDA approval of these requests.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements a
'/>"/>